PCDHB17P

Across TCGA pan-cancer cohorts, PCDHB17P RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PCDHB17P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PCDHB17P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB17P expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

STAD, OV, and CESC are the cancer types where PCDHB17P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.470	0.678	<.001	124	view →
OV	DFS	Tertile	IV	0.594	0.316	.012	50	view →
CESC	DFS	Median	All	0.758	0.869	<.001	50	view →
BLCA	OS	Quartile	II,III,IV	0.624	0.761	.004	39	view →
BRCA	OS	Median	II,III,IV	0.508	0.633	.007	35	view →
LUSC	DFS	Median	III,IV	0.215	0.516	.001	30	view →
THCA	OS	Median	II,III,IV	0.917	0.992	.004	26	view →
UVM	DFS	Median	All	0.542	0.934	.002	22	view →
UCEC	DFS	Tertile	All	0.592	0.725	.005	22	view →
SKCM	DFS	Quartile	All	0.679	0.549	.004	17	view →
READ	OS	Median	All	0.503	0.854	.014	15	view →
DLBC	OS	Median	III,IV	0.272	1.000	.017	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PCDHB17P–STAD (OS)

Open the STAD breakdown →